Unusual Manifestation of an Aldosterone-Producing Adenoma
Primary aldosteronism was first described by Jerome Conn in 1955 in a patient with an aldosterone-producing adrenal adenoma. It’s now a widely recognized cause of secondary hypertension.
Primary aldosteronism was first described by Jerome Conn in 1955 in a patient with an aldosterone-producing adrenal adenoma. It’s now a widely recognized cause of secondary hypertension.
A 43-year-old man was evaluated for uncontrolled hypertension (HTN) despite multiple drug therapy, which included amlodipine 10 mg daily, clonidine 0.3 mg BID, and metoprolol XL 200 mg BID.
It is estimated that about one third of kidney transplant candidates may have a willing, medically fit living donor, but the donor is incompatible because of an unfavorable blood type or the patient has antibodies to the donor’s tissue antigens.
The objectives of partial nephrectomy (PN) for kidney cancer are to optimize cancer control by obtaining negative margins while preserving as much renal function as possible.
Some patients have recurrent nephrolithiasis that may prove refractory to all known preventive strategies. Such individuals can experience frequent bouts of renal colic that result in narcotic dependency, long-term disability, and depression.
The genitourinary tract is the system most frequently affected by congenital defects. Such defects can be solitary or involve multiple organ systems.
Four years ago, a joint effort was established between nephrologists and urologists at the Cleveland Clinic Glickman Urological and Kidney Institute to develop and implant a bioartificial kidney.
Editor’s Note: “On the Forefront” is a new column dedicated to showing how urologists and nephrologists are collaborating on cases to improve patient care.
Renal & Urology News was established in 2002 based on recognition of natural synergies of nephrology and urology. The insight was not immediately intuitive, as care delivery remained largely specialty-based.
Recent therapeutic advances in metastatic renal cell carcinoma (RCC) have included agents targeted against vascular endothelial growth factor (VEGF).